Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by canadafanon Jan 26, 2023 12:42pm

291 Views

Post# 35248032

Where are we at???

What is obvious, low volume both on NAS & TSX.
I can't answer the slide #17 question, other than it looks identical to what is published on their site under " abstracts"
Why low volume?

With lack of solid " new" information those looking to buy are waiting for signals.
A few sellers being obsorbed by market makers & small fry traders.
The rumour mill has been running full tilt regarding takeover- buyout.
That could happen today, tomorrow next quarter, next year or never.

Again & again it comes down to the science.

All of presented abstracts , including one from China partner, lead to great news.